Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.78 |
| ▸ | SRC | P12931 | 8/20 | 0.63 |
| ▸ | KDR | P35968 | 8/20 | 0.63 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | YES1 | P07947 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | CSK | P41240 | 1/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | MST1R | Q04912 | 1/20 | 0.54 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4040743 | 0.94 | EGFR (0.84) | EGFRSRCKDRLCKYES1 | |
| SCHEMBL4033940 | 0.94 | EGFR (0.81) | EGFRSRCKDRLCKYES1 | |
| SCHEMBL4034224 | 0.93 | EGFR (0.80) | EGFRSRCKDRLCKYES1 | |
| SCHEMBL4037402 | 0.93 | EGFR (0.80) | EGFRSRCKDRLCKYES1 | |
| SCHEMBL4032976 | 0.93 | EGFR (0.85) | EGFRSRCKDRLCKYES1 | |
| SCHEMBL4036227 | 0.92 | EGFR (0.92) | EGFRSRCKDRLCKYES1 | |
| SCHEMBL4037003 | 0.92 | EGFR (0.71) | EGFRSRCKDRLCKYES1 | |
| SCHEMBL5662033 | 0.92 | EGFR (0.78) | EGFRSRCKDRLCKYES1 | |
| SCHEMBL4042282 | 0.91 | EGFR (0.82) | EGFRSRCKDR | |
| SCHEMBL4040837 | 0.90 | EGFR (0.75) | EGFRSRCKDRLCKYES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444211-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | EGFR 2/4885SRC 39/4885KDR 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.